Mangoceuticals Sets Series D Terms: $15 Liquidation Preference, 8% Cash Dividends, 3-Year Conversion Lock
MGRX is trading near its 52-week low of $0.15 (3.7% above the low).
Summary
Mangoceuticals disclosed the full terms of its planned 8% Series D convertible preferred: $10 stated value, $15 liquidation preference, cash-only 8% dividends stepping to 10% on default, and no conversion for three years. Existing preferred holders waived their protective provisions to let the senior series rank ahead of them.
Key Events · Financing and Capital Events · MGRX
-
Series D Terms Finalized
A Certificate of Designations effective November 9, 2026 establishes 1,000,000 shares of 8% Series D convertible preferred with a $10.00 stated value and a $15.00 per-share liquidation preference.
-
Cash Dividend Burden
Dividends accrue at $0.80 per share per year, payable solely in cash quarterly, and step up to 10% per annum during any payment default — roughly $800K a year if all 1,000,000 shares are sold.
-
Conversion Price Not Yet Set
The conversion price equals three times the 10-day VWAP before Form 1-A qualification, floored at 20% of the Nasdaq Minimum Price, and conversion is barred until the third anniversary of issuance plus any required stockholder approval.
-
Existing Preferred Waived Protections
Amendments to the Series B and Series C waive variable-rate transaction and repurchase restrictions and subordinate both classes to the new Series D in dividends and liquidation.
Analysis · MGRX · Industrial Applications And Services
The economics of the 8% Series D convertible preferred Mangoceuticals plans to sell under Regulation A are now spelled out, and for a company this small the capital is expensive. Each $10.00 share accrues $0.80 a year in cash-only dividends and ranks ahead of the common, Series B and Series C in liquidation at $15.00 per share — a 150% preference. Holders cannot convert for three years, and the conversion price will be set at three times the 10-day VWAP before the Form 1-A is qualified, so the eventual share count depends on where the stock trades at that moment. Against a $0.155 stock price, a 3x-VWAP formula implies a conversion price far above today's level, which limits near-term dilution but also makes the paper unattractive to convert — leaving the cash dividend as the real cost. To let this happen, Series B and Series C holders waived their variable-rate and repurchase protections, subordinating their claims and removing guardrails that previously limited new senior paper. With cash of $229K as of the last 10-Q, a going-concern warning and a pending reverse-split proxy to cure the Nasdaq bid-price deficiency, this is survival financing priced accordingly.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.15 to $2.28. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.